aTyr Pharma Statistics

Total Valuation

aTyr Pharma has a market cap or net worth of EUR 69.40 million. The enterprise value is 2.32 million.

Market Cap	69.40M
Enterprise Value	2.32M

Important Dates

The next estimated earnings date is Monday, March 16, 2026.

Earnings Date	Mar 16, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	97.99M
Shares Outstanding	n/a
Shares Change (YoY)	+30.37%
Shares Change (QoQ)	+7.80%
Owned by Insiders (%)	2.49%
Owned by Institutions (%)	62.24%
Float	95.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	428.54
PB Ratio	1.02
P/TBV Ratio	1.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.04
EV / Sales	14.20
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.04

Financial Position

The company has a current ratio of 5.93, with a Debt / Equity ratio of 0.15.

Current Ratio	5.93
Quick Ratio	5.82
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	-0.20
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -103.49% and return on invested capital (ROIC) is -57.46%.

Return on Equity (ROE)	-103.49%
Return on Assets (ROA)	-49.59%
Return on Invested Capital (ROIC)	-57.46%
Return on Capital Employed (ROCE)	-86.45%
Revenue Per Employee	2,655
Profits Per Employee	-1.05M
Employee Count	65
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-82.17%
50-Day Moving Average	0.66
200-Day Moving Average	2.91
Relative Strength Index (RSI)	47.74
Average Volume (20 Days)	325

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.80

Income Statement

In the last 12 months, aTyr Pharma had revenue of EUR 161,937 and -64.03 million in losses. Loss per share was -0.72.

Revenue	161,937
Gross Profit	-52.30M
Operating Income	-67.03M
Pretax Income	-64.03M
Net Income	-64.03M
EBITDA	-66.46M
EBIT	-67.03M
Loss Per Share	-0.72

Full Income Statement

Balance Sheet

The company has 76.88 million in cash and 10.53 million in debt, giving a net cash position of 66.35 million.

Cash & Cash Equivalents	76.88M
Total Debt	10.53M
Net Cash	66.35M
Net Cash Per Share	n/a
Equity (Book Value)	68.22M
Book Value Per Share	0.70
Working Capital	65.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -53.63 million and capital expenditures -60,513, giving a free cash flow of -53.69 million.

Operating Cash Flow	-53.63M
Capital Expenditures	-60,513
Free Cash Flow	-53.69M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-41,395.26%
Pretax Margin	-39,540.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

aTyr Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.37%
Shareholder Yield	-30.37%
Earnings Yield	-92.26%
FCF Yield	-77.37%

Stock Splits

The last stock split was on July 1, 2019. It was a reverse split with a ratio of 0.0714285714.

Last Split Date	Jul 1, 2019
Split Type	Reverse
Split Ratio	0.0714285714

Scores

aTyr Pharma has an Altman Z-Score of -1.84 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.84
Piotroski F-Score	2